Cisapride (R 51619): Benchmarks in Cardiac Electrophysiology

Executive Summary: Cisapride (R 51619) is a nonselective 5-HT4 receptor agonist and potent inhibitor of the hERG potassium channel, central to cardiac electrophysiology research (source: product_spec). It is widely employed as a reference compound to model drug-induced arrhythmias in iPSC-derived cardiomyocyte assays (source: paper). High content screening platforms routinely use Cisapride to validate detection of cardiotoxicity and benchmark assay sensitivity (source: paper). The APExBIO B1198 formulation provides >99.7% purity and robust solubility in DMSO and ethanol, but is insoluble in water, ensuring reliable performance in standard protocols (source: product_spec). This article clarifies Cisapride’s validated applications, protocol parameters, and common pitfalls, referencing recent advances in phenotypic screening and predictive safety workflows.

Biological Rationale

Cisapride is chemically defined as 4-amino-5-chloro-N-((3S,4R)-1-(3-(4-fluorophenoxy)propyl)-3-methoxypiperidin-4-yl)-2-methoxybenzamide, with a molecular weight of 465.95 and molecular formula C23H29ClFN3O4 (source: product_spec). The compound’s dual pharmacology—activation of serotonin 5-HT4 receptors and inhibition of hERG potassium channels—underpins its value in translational research. The 5-HT4 receptor pathway is implicated in gastrointestinal motility and cardiac function, while hERG channel inhibition is a canonical mechanism underlying drug-induced QT prolongation and arrhythmia (source: paper). Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) recapitulate key aspects of cardiac electrophysiology, enabling in vitro interrogation of arrhythmogenic risk and toxicological profiles (source: paper).

Mechanism of Action of Cisapride

Cisapride acts as a nonselective agonist at 5-HT4 serotonin receptors, increasing intracellular cAMP and modulating cardiac and gut motility pathways (source: internal_article). Critically, it is a potent inhibitor of the hERG (human ether-à-go-go-related gene) potassium channel, encoded by KCNH2, which mediates the I_Kr current responsible for cardiac repolarization. Inhibition of hERG leads to QT interval prolongation and heightened risk of torsades de pointes and other arrhythmias (source: paper). This dual mechanism allows Cisapride to serve as both a tool for 5-HT4 pathway interrogation and a reference standard in cardiac safety assays designed to detect proarrhythmic liabilities (source: internal_article, contrasts mechanistic focus; this article benchmarks translational utility).

Evidence & Benchmarks

• Cisapride induces dose-dependent action potential duration (APD) prolongation in iPSC-CMs, confirming hERG channel blockade as the primary mechanism (source: paper).
• High-content screening using deep learning detects Cisapride-induced cardiotoxicity with high specificity and sensitivity in iPSC-CMs (source: paper).
• APExBIO B1198 Cisapride is supplied at >99.7% purity, validated by HPLC, NMR, and MSDS, supporting reproducible experimental outcomes (source: product_spec).
• Cisapride is highly soluble in DMSO (≥23.3 mg/mL) and ethanol (≥3.47 mg/mL), facilitating stock solution preparation for screening platforms (source: product_spec).
• iPSC-CMs exposed to Cisapride serve as a benchmark for validating new phenotypic screening platforms targeting arrhythmogenic risk (source: paper).

For further mechanistic guidance, see 'Cisapride (R 51619): Precision Tool for Cardiac Electrophysiology', which provides troubleshooting and workflow optimization strategies. This article extends that discussion by integrating recent deep learning-enabled screening evidence.

Applications, Limits & Misconceptions

Cisapride’s dual action enables use in both cardiac electrophysiology and serotonergic pathway investigations. Its validated role as a hERG inhibitor makes it a critical control for predictive cardiotoxicity assays. However, its insolubility in water and nonselectivity at 5-HT4 receptors require careful protocol design (source: product_spec).

Common Pitfalls or Misconceptions

• Assuming water solubility: Cisapride is insoluble in water; DMSO or ethanol must be used for stock solutions (source: product_spec).
• Overestimating selectivity: Cisapride is nonselective for 5-HT4 and has potent hERG inhibition; off-target effects may confound data (source: internal_article).
• Long-term solution storage: Working solutions degrade; use immediately after preparation for best results (source: product_spec).
• Diagnostic/therapeutic use: Cisapride supplied by APExBIO is for research use only and not for clinical applications (source: product_spec).
• Assuming all cardiomyocyte models are equivalent: iPSC-derived cardiomyocytes reflect human physiology more closely than immortalized lines (source: paper).

Workflow Integration & Parameters

Integration of Cisapride into cardiac electrophysiology and predictive toxicology workflows requires attention to source purity, solvent compatibility, and model system selection. APExBIO B1198 is optimized for use in iPSC-CM phenotypic screening and high-throughput workflows (source: product_spec).

Protocol Parameters

• assay: iPSC-CM APD prolongation | value_with_unit: 10–1000 nM | applicability: in vitro arrhythmia modeling | rationale: matches reported IC₅₀ for hERG inhibition | source_type: paper (DOI)
• assay: Compound solubility | value_with_unit: ≥23.3 mg/mL in DMSO, ≥3.47 mg/mL in ethanol | applicability: stock solution preparation | rationale: ensures accurate dosing in screening assays | source_type: product_spec (spec)
• assay: Storage temperature | value_with_unit: -20°C | applicability: long-term compound stability | rationale: preserves integrity and purity | source_type: product_spec (spec)
• assay: Working solution stability | value_with_unit: use immediately, do not store | applicability: experimental reproducibility | rationale: prevents degradation and loss of potency | source_type: workflow_recommendation

For broader translational context, see 'Translating Mechanistic Insight into Predictive Safety', which discusses strategic use of Cisapride in deep learning-enabled cardiac risk assessment. This article updates the evidence base with quantitative benchmarks and protocol specifics.

Conclusion & Outlook

Cisapride (R 51619) remains a gold-standard reference for hERG channel inhibition and 5-HT4 receptor pathway interrogation in cardiac electrophysiology research. Its validated use in iPSC-derived cardiomyocyte platforms, supported by high-content screening and deep learning analytics, enables robust prediction of drug-induced arrhythmia risk (source: paper). The availability of high-purity material from APExBIO (B1198) streamlines workflow integration. Ongoing advances in phenotypic screening and iPSC-CM model systems are expected to refine predictive safety paradigms, but correct solvent use, model selection, and workflow discipline remain essential for experimental reliability.